Eagle's Eye View: Your Weekly CV Update From ACC.org Podcast By American College of Cardiology cover art

Eagle's Eye View: Your Weekly CV Update From ACC.org

Eagle's Eye View: Your Weekly CV Update From ACC.org

By: American College of Cardiology
Listen for free

The weekly cardiovascular update from Kim Eagle, MD, MACC for ACC.org covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.American College of Cardiology Foundation. All rights reserved. Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • Top Takeaways from ACC.26

    Top Takeaways from ACC.26
    Apr 8 2026
    In this week's View, Dr. Eagle highlights trials from the recently held ACC Scientific Sessions which took place in New Orleans, March 28-30. Important studies discussed include: CHAMPION-AF: Left atrial appendage closure vs. anticoagulation for AFib VESALIUS-CV: Evolocumab reduces CV risk in diabetic patients without ASCVD Ez-PAVE: Hitting lower LDL-C target reduces major CV events PRO-TAVI: Should high-risk patients undergo PCI before TAVI? SMART-DECISION: Discontinuing beta-blockers safe 1 year post MI For stable patients GoFreshRx: How home-delivered DASH groceries improve blood pressure (BP) and LDL-C THRIVE: Exploring the positive effects of a culturally tailored "food-is medicine" program on lowering BP  
    Show more Show less
    11 mins
  • New ACC/AHA Dyslipidemia Guidelines Released

    New ACC/AHA Dyslipidemia Guidelines Released
    Mar 18 2026

    In this week's View, Dr. Eagle looks at data from the STS/ACC TVT Registry on off-label transcatheter valve interventions that demonstrate reduced residual tricuspid regurgitation (TR) and improved quality of life. He then explores the REVNOVATE-COMPLEX-PCI study that investigates the benefits of intravascular imaging guidance for five years. Finally, Dr. Eagle summarizes the ACC/AHA's newly released clinical guidelines for managing dyslipidemia.

     Subscribe to Eagle's Eye View  

    Show more Show less
    8 mins
  • Beta-Blocker vs. Calcium-Channel Blocker in HCM

    Beta-Blocker vs. Calcium-Channel Blocker in HCM
    Mar 11 2026
    In this week's View, Dr. Eagle looks at the differential effect of bisoprolol versus verapamil in nonobstructive hypertrophic cardiomyopathy (HCM) treatment. He then explores lower heart failure (HF) hospitalization risk in patients with type 2 diabetes, comparing GLP-1RAs to DPP-4 inhibitors and similar outcomes with SGLT-2 inhibitors. Dr. Eagle then examines the use of shared decision-making and decision aids in percutaneous left atrial appendage occlusion (LAAO). Finally, the iModern trial, which compares immediate percutaneous coronary intervention (PCI) guided by instantaneous wave-free ratio (iFR) and deferred PCI guided by cardiac stress magnetic resonance imaging (MRI) in patients with STEMI and multivessel disease, is discussed.  Subscribe to Eagle's Eye View  
    Show more Show less
    9 mins
No reviews yet